Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Tumour-associated neutrophils in patients with cancer.

Shaul ME, Fridlender ZG.

Nat Rev Clin Oncol. 2019 Jun 3. doi: 10.1038/s41571-019-0222-4. [Epub ahead of print] Review.

PMID:
31160735
2.

Neutrophil Diversity in Health and Disease.

Silvestre-Roig C, Fridlender ZG, Glogauer M, Scapini P.

Trends Immunol. 2019 May 31. pii: S1471-4906(19)30101-2. doi: 10.1016/j.it.2019.04.012. [Epub ahead of print] Review.

PMID:
31160207
3.

Interactions among myeloid regulatory cells in cancer.

Umansky V, Adema GJ, Baran J, Brandau S, Van Ginderachter JA, Hu X, Jablonska J, Mojsilovic S, Papadaki HA, Pico de Coaña Y, Santegoets KCM, Santibanez JF, Serre K, Si Y, Sieminska I, Velegraki M, Fridlender ZG.

Cancer Immunol Immunother. 2019 Apr;68(4):645-660. doi: 10.1007/s00262-018-2200-6. Epub 2018 Jul 12. Review.

PMID:
30003321
4.

Microenvironmental Cues Determine Tumor Cell Susceptibility to Neutrophil Cytotoxicity.

Gershkovitz M, Fainsod-Levi T, Khawaled S, Shaul ME, Sionov RV, Cohen-Daniel L, Aqeilan RI, Shaul YD, Fridlender ZG, Granot Z.

Cancer Res. 2018 Sep 1;78(17):5050-5059. doi: 10.1158/0008-5472.CAN-18-0540. Epub 2018 Jul 2.

PMID:
29967257
5.

Cancer-related circulating and tumor-associated neutrophils - subtypes, sources and function.

Shaul ME, Fridlender ZG.

FEBS J. 2018 Dec;285(23):4316-4342. doi: 10.1111/febs.14524. Epub 2018 Jun 14. Review.

PMID:
29851227
6.

Myeloid Regulatory Cells: New and Exciting Players in the Immunology of Lung Cancer.

Fridlender ZG.

Am J Respir Crit Care Med. 2018 Sep 15;198(6):703-704. doi: 10.1164/rccm.201804-0742ED. No abstract available.

PMID:
29758167
7.

TRPM2 Mediates Neutrophil Killing of Disseminated Tumor Cells.

Gershkovitz M, Caspi Y, Fainsod-Levi T, Katz B, Michaeli J, Khawaled S, Lev S, Polyansky L, Shaul ME, Sionov RV, Cohen-Daniel L, Aqeilan RI, Shaul YD, Mori Y, Karni R, Fridlender ZG, Binshtok AM, Granot Z.

Cancer Res. 2018 May 15;78(10):2680-2690. doi: 10.1158/0008-5472.CAN-17-3614. Epub 2018 Feb 28.

8.

Inhaled therapies in patients with moderate COPD in clinical practice: current thinking.

Ariel A, Altraja A, Belevskiy A, Boros PW, Danila E, Fležar M, Koblizek V, Fridlender ZG, Kostov K, Krams A, Milenkovic B, Somfay A, Tkacova R, Tudoric N, Ulmeanu R, Valipour A.

Int J Chron Obstruct Pulmon Dis. 2017 Dec 21;13:45-56. doi: 10.2147/COPD.S145573. eCollection 2018. Review.

9.

Tumor-associated neutrophils induce apoptosis of non-activated CD8 T-cells in a TNFα and NO-dependent mechanism, promoting a tumor-supportive environment.

Michaeli J, Shaul ME, Mishalian I, Hovav AH, Levy L, Zolotriov L, Granot Z, Fridlender ZG.

Oncoimmunology. 2017 Aug 16;6(11):e1356965. doi: 10.1080/2162402X.2017.1356965. eCollection 2017.

10.

Control of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy?

Tan LY, Martini C, Fridlender ZG, Bonder CS, Brown MP, Ebert LM.

Clin Transl Immunology. 2017 Mar 17;6(3):e134. doi: 10.1038/cti.2017.7. eCollection 2017 Mar. Review.

11.

Neutrophils as active regulators of the immune system in the tumor microenvironment.

Shaul ME, Fridlender ZG.

J Leukoc Biol. 2017 Aug;102(2):343-349. doi: 10.1189/jlb.5MR1216-508R. Epub 2017 Mar 6. Review.

PMID:
28264904
12.

The association between osteopontin gene polymorphisms, osteopontin expression and sarcoidosis.

Lavi H, Assayag M, Schwartz A, Arish N, Fridlender ZG, Berkman N.

PLoS One. 2017 Mar 2;12(3):e0171945. doi: 10.1371/journal.pone.0171945. eCollection 2017.

13.

Organizing pneumonia following treatment with pembrolizumab for metastatic malignant melanoma - A case report.

Kuint R, Lotem M, Neuman T, Bekker-Milovanov E, Abutbul A, Laxer U, Berkman N, Fridlender ZG.

Respir Med Case Rep. 2017 Jan 12;20:95-97. doi: 10.1016/j.rmcr.2017.01.003. eCollection 2017.

14.

Tumor-associated neutrophils display a distinct N1 profile following TGFβ modulation: A transcriptomics analysis of pro- vs. antitumor TANs.

Shaul ME, Levy L, Sun J, Mishalian I, Singhal S, Kapoor V, Horng W, Fridlender G, Albelda SM, Fridlender ZG.

Oncoimmunology. 2016 Sep 13;5(11):e1232221. doi: 10.1080/2162402X.2016.1232221. eCollection 2016.

15.

Endobrochial Ultrasound Needle Breakdown During Transbronchial Needle Aspiration.

Kuint R, Abutbul A, Fridlender ZG, Berkman N.

J Bronchology Interv Pulmonol. 2016 Jul;23(3):e32-3. doi: 10.1097/LBR.0000000000000295. No abstract available.

PMID:
27454481
16.

The diversity of circulating neutrophils in cancer.

Mishalian I, Granot Z, Fridlender ZG.

Immunobiology. 2017 Jan;222(1):82-88. doi: 10.1016/j.imbio.2016.02.001. Epub 2016 Feb 3. Review.

PMID:
26874580
17.

Plasticity beyond cancer cells and the "immunosuppressive switch".

Granot Z, Fridlender ZG.

Cancer Res. 2015 Nov 1;75(21):4441-5. doi: 10.1158/0008-5472.CAN-15-1502. Epub 2015 Oct 16. Review.

18.

Cluster of Fusarium solani isolations in a Bronchoscopy Unit.

Levy L, Block C, Schwartz C, Gross I, Cohen M, Fridlender ZG, Moses AE, Berkman N, Benenson S.

Clin Microbiol Infect. 2016 Jan;22(1):e5-e6. doi: 10.1016/j.cmi.2015.09.017. Epub 2015 Sep 28. No abstract available.

19.

Recurrent Eosinophilic Pneumonia in a Patient with Isolated Immunoglobulin M Deficiency and Celiac Disease.

Chen S, Shamriz O, Toker O, Fridlender ZG, Tal Y.

Isr Med Assoc J. 2015 Aug;17(8):526-7. No abstract available.

20.

Promoting metastasis: neutrophils and T cells join forces.

Fridlender ZG, Albelda SM, Granot Z.

Cell Res. 2015 Jul;25(7):765-6. doi: 10.1038/cr.2015.62. Epub 2015 May 26.

21.

Splenectomy inhibits non-small cell lung cancer growth by modulating anti-tumor adaptive and innate immune response.

Levy L, Mishalian I, Bayuch R, Zolotarov L, Michaeli J, Fridlender ZG.

Oncoimmunology. 2015 Jan 22;4(4):e998469. eCollection 2015 Apr.

22.

Isolation and Characterization of Neutrophils with Anti-Tumor Properties.

Sionov RV, Assi S, Gershkovitz M, Sagiv JY, Polyansky L, Mishalian I, Fridlender ZG, Granot Z.

J Vis Exp. 2015 Jun 19;(100):e52933. doi: 10.3791/52933.

23.

Surgical cytoreduction restores the antitumor efficacy of a Listeria monocytogenes vaccine in malignant pleural mesothelioma.

Kennedy GT, Judy BF, Bhojnagarwala P, Moon EK, Fridlender ZG, Albelda SM, Singhal S.

Immunol Lett. 2015 Jul;166(1):28-35. doi: 10.1016/j.imlet.2015.05.009. Epub 2015 May 18.

24.

Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer.

Sagiv JY, Michaeli J, Assi S, Mishalian I, Kisos H, Levy L, Damti P, Lumbroso D, Polyansky L, Sionov RV, Ariel A, Hovav AH, Henke E, Fridlender ZG, Granot Z.

Cell Rep. 2015 Feb 3;10(4):562-73. doi: 10.1016/j.celrep.2014.12.039. Epub 2015 Jan 22.

25.

The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment.

Sionov RV, Fridlender ZG, Granot Z.

Cancer Microenviron. 2015 Dec;8(3):125-58. doi: 10.1007/s12307-014-0147-5. Epub 2014 Jun 4.

26.

Neutrophils recruit regulatory T-cells into tumors via secretion of CCL17--a new mechanism of impaired antitumor immunity.

Mishalian I, Bayuh R, Eruslanov E, Michaeli J, Levy L, Zolotarov L, Singhal S, Albelda SM, Granot Z, Fridlender ZG.

Int J Cancer. 2014 Sep 1;135(5):1178-86. doi: 10.1002/ijc.28770. Epub 2014 Feb 27.

27.

Modifying tumor-associated macrophages: An important adjunct to immunotherapy.

Fridlender ZG, Albelda SM.

Oncoimmunology. 2013 Dec 1;2(12):e26620. Epub 2013 Oct 21.

28.

Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression.

Mishalian I, Bayuh R, Levy L, Zolotarov L, Michaeli J, Fridlender ZG.

Cancer Immunol Immunother. 2013 Nov;62(11):1745-56. doi: 10.1007/s00262-013-1476-9. Epub 2013 Oct 4.

PMID:
24092389
29.

Using macrophage activation to augment immunotherapy of established tumours.

Fridlender ZG, Jassar A, Mishalian I, Wang LC, Kapoor V, Cheng G, Sun J, Singhal S, Levy L, Albelda SM.

Br J Cancer. 2013 Apr 2;108(6):1288-97. doi: 10.1038/bjc.2013.93. Epub 2013 Mar 12.

30.

Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery.

Predina J, Eruslanov E, Judy B, Kapoor V, Cheng G, Wang LC, Sun J, Moon EK, Fridlender ZG, Albelda S, Singhal S.

Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):E415-24. doi: 10.1073/pnas.1211850110. Epub 2012 Dec 27.

31.

Randomized controlled crossover trial of a new oscillatory device as add-on therapy for COPD.

Fridlender ZG, Arish N, Laxer U, Berkman N, Leibovitz A, Fink G, Breuer R.

COPD. 2012 Dec;9(6):603-10. doi: 10.3109/15412555.2012.748625. Epub 2012 Dec 6.

PMID:
23215916
32.

Cytoreduction surgery reduces systemic myeloid suppressor cell populations and restores intratumoral immunotherapy effectiveness.

Predina JD, Kapoor V, Judy BF, Cheng G, Fridlender ZG, Albelda SM, Singhal S.

J Hematol Oncol. 2012 Jun 28;5:34. doi: 10.1186/1756-8722-5-34.

33.

A positive-margin resection model recreates the postsurgical tumor microenvironment and is a reliable model for adjuvant therapy evaluation.

Predina JD, Judy B, Fridlender ZG, Aliperti LA, Madajewski B, Kapoor V, Cheng G, Quatromoni J, Okusanya O, Singhal S.

Cancer Biol Ther. 2012 Jul;13(9):745-55. Epub 2012 May 23.

34.

Characterization of surgical models of postoperative tumor recurrence for preclinical adjuvant therapy assessment.

Predina JD, Judy B, Kapoor V, Blouin A, Aliperti LA, Levine D, Okusanya OT, Quatromoni J, Fridlender ZG, Singhal S.

Am J Transl Res. 2012;4(2):206-18. Epub 2012 Apr 10.

35.

Tumor-associated neutrophils: friend or foe?

Fridlender ZG, Albelda SM.

Carcinogenesis. 2012 May;33(5):949-55. doi: 10.1093/carcin/bgs123. Epub 2012 Mar 16. Review.

PMID:
22425643
36.

Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils.

Fridlender ZG, Sun J, Mishalian I, Singhal S, Cheng G, Kapoor V, Horng W, Fridlender G, Bayuh R, Worthen GS, Albelda SM.

PLoS One. 2012;7(2):e31524. doi: 10.1371/journal.pone.0031524. Epub 2012 Feb 14.

37.

Treating tumors with a vaccinia virus expressing IFNβ illustrates the complex relationships between oncolytic ability and immunogenicity.

Wang LC, Lynn RC, Cheng G, Alexander E, Kapoor V, Moon EK, Sun J, Fridlender ZG, Isaacs SN, Thorne SH, Albelda SM.

Mol Ther. 2012 Apr;20(4):736-48. doi: 10.1038/mt.2011.228. Epub 2011 Oct 18.

38.

Neoadjuvant in situ gene-mediated cytotoxic immunotherapy improves postoperative outcomes in novel syngeneic esophageal carcinoma models.

Predina JD, Judy B, Aliperti LA, Fridlender ZG, Blouin A, Kapoor V, Laguna B, Nakagawa H, Rustgi AK, Aguilar L, Aguilar-Cordova E, Albelda SM, Singhal S.

Cancer Gene Ther. 2011 Dec;18(12):871-83. doi: 10.1038/cgt.2011.56. Epub 2011 Aug 26.

39.

Activation of mitogen-activated protein kinases by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) plays an important role in macrophage stimulation.

Sun J, Wang LC, Fridlender ZG, Kapoor V, Cheng G, Ching LM, Albelda SM.

Biochem Pharmacol. 2011 Nov 1;82(9):1175-85. doi: 10.1016/j.bcp.2011.07.086. Epub 2011 Jul 26.

40.

Sildenafil to facilitate weaning from inhaled nitric oxide and mechanical ventilation in a patient with severe secondary pulmonary hypertension and a patent foramen ovale.

Elias S, Sviri S, Orenbuch-Harroch E, Fellig Y, Ben-Yehuda A, Fridlender ZG, Gilon D, Bayya A.

Respir Care. 2011 Oct;56(10):1611-3. doi: 10.4187/respcare.01147. Epub 2011 Apr 19.

41.

Pharmacologic activation of the innate immune system to prevent respiratory viral infections.

Cheng G, Wang LC, Fridlender ZG, Cheng GS, Chen B, Mangalmurti NS, Saloura V, Yu Z, Kapoor V, Mozdzanowska K, Moon E, Sun J, Kreindler JL, Cohen NA, Caton AJ, Erikson J, Albelda SM.

Am J Respir Cell Mol Biol. 2011 Sep;45(3):480-8. doi: 10.1165/rcmb.2010-0288OC. Epub 2010 Dec 10.

42.

Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms.

Fridlender ZG, Sun J, Singhal S, Kapoor V, Cheng G, Suzuki E, Albelda SM.

Mol Ther. 2010 Nov;18(11):1947-59. doi: 10.1038/mt.2010.159. Epub 2010 Aug 3.

43.

Association between CD14 gene polymorphisms and disease phenotype in sarcoidosis.

Fridlender ZG, Schwartz A, Kohan M, Amir G, Glazer M, Berkman N.

Respir Med. 2010 Sep;104(9):1336-43. doi: 10.1016/j.rmed.2010.03.029. Epub 2010 Apr 28.

44.

Monocyte chemoattractant protein-1 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells.

Fridlender ZG, Kapoor V, Buchlis G, Cheng G, Sun J, Wang LC, Singhal S, Snyder LA, Albelda SM.

Am J Respir Cell Mol Biol. 2011 Feb;44(2):230-7. doi: 10.1165/rcmb.2010-0080OC. Epub 2010 Apr 15.

45.

Exogenous lipoid pneumonia caused by paraffin in an amateur fire breather.

Weinberg I, Fridlender ZG.

Occup Med (Lond). 2010 May;60(3):234-5. doi: 10.1093/occmed/kqq020. Epub 2010 Mar 22.

PMID:
20308260
46.

Activation of the nucleotide oligomerization domain signaling pathway by the non-bacterially derived xanthone drug 5'6-dimethylxanthenone-4-acetic acid (Vadimezan).

Cheng G, Sun J, Fridlender ZG, Wang LC, Ching LM, Albelda SM.

J Biol Chem. 2010 Apr 2;285(14):10553-62. doi: 10.1074/jbc.M109.065631. Epub 2010 Jan 29.

47.

CCL2 blockade augments cancer immunotherapy.

Fridlender ZG, Buchlis G, Kapoor V, Cheng G, Sun J, Singhal S, Crisanti MC, Wang LC, Heitjan D, Snyder LA, Albelda SM.

Cancer Res. 2010 Jan 1;70(1):109-18. doi: 10.1158/0008-5472.CAN-09-2326. Epub 2009 Dec 22. Erratum in: Cancer Res. 2010 Mar 15;70(6):2569. Crisanti, Cecilia [corrected to Crisanti, M Cecilia].

48.

Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma.

Willmon CL, Saloura V, Fridlender ZG, Wongthida P, Diaz RM, Thompson J, Kottke T, Federspiel M, Barber G, Albelda SM, Vile RG.

Cancer Res. 2009 Oct 1;69(19):7713-20. doi: 10.1158/0008-5472.CAN-09-1013. Epub 2009 Sep 22.

49.

Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN.

Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SM.

Cancer Cell. 2009 Sep 8;16(3):183-94. doi: 10.1016/j.ccr.2009.06.017.

50.

Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy.

Saloura V, Wang LC, Fridlender ZG, Sun J, Cheng G, Kapoor V, Sterman DH, Harty RN, Okumura A, Barber GN, Vile RG, Federspiel MJ, Russell SJ, Litzky L, Albelda SM.

Hum Gene Ther. 2010 Jan;21(1):51-64. doi: 10.1089/hum.2009.088.

Supplemental Content

Loading ...
Support Center